We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+9.66%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$89.3B
AUM Growth
+$8.23B
Cap. Flow
+$1.9B
Cap. Flow %
2.12%
Top 10 Hldgs %
24.87%
Holding
4,460
New
1,490
Increased
1,679
Reduced
1,235
Closed
38

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$60.1M
2
TSM icon
TSMC
TSM
+$59.1M
3
TSLA icon
Tesla
TSLA
+$56M
4
AAPL icon
Apple
AAPL
+$55.2M
5
AMZN icon
Amazon
AMZN
+$47.5M

Top Sells

Rank Stock Value
1
ACWX icon
iShares MSCI ACWI ex US ETF
ACWX
+$102M
2
EG icon
Everest Group
EG
+$27.4M
3
CVX icon
Chevron
CVX
+$25M
4
WFC icon
Wells Fargo
WFC
+$24.9M
5
CXT icon
Crane NXT
CXT
+$13.5M

Sector Composition

Rank Sector Weight
1 Technology 27.27%
2 Healthcare 12.98%
3 Financials 12.17%
4 Consumer Discretionary 11.18%
5 Industrials 9.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DAVE icon
3851
Dave Inc
DAVE
$4.64B
$1.35K ﹤0.01%
+254
New +$1.38K
AXDX
3852
DELISTED
Accelerate Diagnostics
AXDX
$1.33K ﹤0.01%
+164
New +$1.23K
LTRN icon
3853
Lantern Pharma
LTRN
$35.5M
$1.28K ﹤0.01%
+228
New +$1.18K
RANI icon
3854
Rani Therapeutics
RANI
$87.8M
$1.28K ﹤0.01%
+312
New +$1.45K
GROW icon
3855
US Global Investors
GROW
$38.5M
$1.28K ﹤0.01%
+417
New +$1.16K
SNCR
3856
DELISTED
Synchronoss Technologies
SNCR
$1.27K ﹤0.01%
+152
New +$1.28K
NXTC icon
3857
NextCure
NXTC
$22.7M
$1.26K ﹤0.01%
+59
New +$1.16K
EMKR
3858
DELISTED
Emcore Corp
EMKR
$1.26K ﹤0.01%
+168
New +$1.52K
CCJ icon
3859
Cameco
CCJ
$40.8B
$1.25K ﹤0.01%
+40
New +$1.13K
CLSD
3860
DELISTED
Clearside Biomedical
CLSD
$1.22K ﹤0.01%
+73
New +$1.26K
LYRA
3861
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.22K ﹤0.01%
+6
New +$833
BFX
3862
DELISTED
BowFlex Inc.
BFX
$1.19K ﹤0.01%
+975
New +$1.24K
AXR icon
3863
AMREP Corp
AXR
$117M
$1.18K ﹤0.01%
+66
New +$996
MHH icon
3864
Mastech Digital
MHH
$95.7M
$1.17K ﹤0.01%
+118
New +$1.16K
RIDE
3865
DELISTED
Lordstown Motors Corp. Class A Common Stock
RIDE
$1.16K ﹤0.01%
545
-44,068
-99% -$231K
TECX
3866
Tectonic Therapeutic
TECX
$570M
$1.15K ﹤0.01%
+101
New +$1.14K
DUO
3867
Fangdd Network Group
DUO
$22.8M
$1.14K ﹤0.01%
+5
New +$1.06K
WKEY
3868
WISeKey
WKEY
$75.6M
$1.09K ﹤0.01%
+248
New +$1.41K
BBIG
3869
DELISTED
Vinco Ventures, Inc. Common Stock
BBIG
$1.08K ﹤0.01%
886
-14,297
-94% -$43.9K
CODX
3870
Co-Diagnostics
CODX
$5.23M
$1.08K ﹤0.01%
+32
New +$1.22K
AINC
3871
DELISTED
Ashford Inc.
AINC
$1.07K ﹤0.01%
+110
New +$1.16K
SCOR icon
3872
Comscore
SCOR
$113M
$1.06K ﹤0.01%
+66
New +$1.26K
CISO
3873
CISO Global
CISO
$12.2M
$1.06K ﹤0.01%
396
-3,563
-90% -$11.9K
QTTB icon
3874
Q32 Bio
QTTB
$482M
$1.04K ﹤0.01%
+65
New +$1.17K
SOHO
3875
DELISTED
Sotherly Hotels
SOHO
$1.01K ﹤0.01%
+533
New +$1.01K

Similar funds

RhumbLine Advisers's Q2 2023 Portfolio in Review

As of Q2 2023, RhumbLine Advisers held 4,460 positions worth $89.3B, up 10% from $81B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

RhumbLine Advisers's Q2 2023 filing shows 1,490 new, 1,679 increased, 1,235 reduced and 38 closed positions. Its largest new stake was TSMC: 635,517 shares worth $64.1M. The largest sale was iShares MSCI ACWI ex US ETF, an estimated $102M.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.

  • RhumbLine Advisers's largest Q2 2023 buy was TSMC: 635,517 shares worth $64.1M.
  • RhumbLine Advisers added most to Microsoft in Q2 2023, an estimated $60.1M increase.
  • RhumbLine Advisers's biggest Q2 2023 reduction was iShares MSCI ACWI ex US ETF, cutting an estimated $102M.
  • RhumbLine Advisers fully exited Everest Group in Q2 2023, selling an estimated $27.4M.
  • RhumbLine Advisers's ten largest holdings make up 25% of its $89.3B portfolio in Q2 2023.
  • RhumbLine Advisers opened 1,490 new positions and closed 38 in Q2 2023.
  • RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $89.3B.

Based on RhumbLine Advisers's 13F filing for Q2 2023, filed 8 Aug 2023.